{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T06:00:34Z","timestamp":1789365634618,"version":"build-2803163510"},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.diagmicrobio.2012.05.012","type":"journal-article","created":{"date-parts":[[2012,6,15]],"date-time":"2012-06-15T19:14:03Z","timestamp":1339787643000},"page":"54-61","source":"Crossref","is-referenced-by-count":43,"title":["LEADER Surveillance program results for 2010: an activity and spectrum analysis of linezolid using 6801 clinical isolates from the United States (61 medical centers)"],"prefix":"10.1016","volume":"74","author":[{"given":"Robert K.","family":"Flamm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Farrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo E.","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald N.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2012.05.012_bb0005","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ijantimicag.2005.02.019","article-title":"Trends in linezolid susceptibility patterns: report from the 2002\u20132003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program","volume":"26","author":"Anderegg","year":"2005","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2012.05.012_bb0010","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1128\/JCM.01886-07","article-title":"Clinical and microbiological aspects of linezolid resistance mediated by the cfr gene encoding a 23S rRNA methyltransferase","volume":"46","author":"Arias","year":"2008","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2012.05.012_bb0015","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1086\/656281","article-title":"Multicity outbreak of linezolid-resistant Staphylococcus epidermidis associated with clonal spread of a cfr-containing strain","volume":"51","author":"Bonilla","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2012.05.012_bb0020","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2174\/1381612802666220921173820","article-title":"Oxazolidinone antibacterial agents","volume":"2","author":"Brickner","year":"1996","journal-title":"Curr Pharm Design"},{"key":"10.1016\/j.diagmicrobio.2012.05.012_bb0025","series-title":"Performance standards for antimicrobial disk susceptibility tests; approved standard - tenth edition, M02-A10","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2009"},{"key":"10.1016\/j.diagmicrobio.2012.05.012_bb0030","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard - eighth edition, M07-A8","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2009"},{"key":"10.1016\/j.diagmicrobio.2012.05.012_bb0035","series-title":"Performance standards for antimicrobial susceptibility testing: 21st informational supplement (M100-S21)","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2011"},{"key":"10.1016\/j.diagmicrobio.2012.05.012_bb0040","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0140-6736(01)06964-1","article-title":"Oxazolidinone antibiotics","volume":"358","author":"Diekema","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.diagmicrobio.2012.05.012_bb0050","doi-asserted-by":"crossref","first-page":"5024","DOI":"10.1128\/AAC.49.12.5024-5032.2005","article-title":"In vitro activity of linezolid against key Gram-positive organisms isolated in the United States: results of the LEADER 2004 surveillance program","volume":"49","author":"Draghi","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2012.05.012_bb0045","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.diagmicrobio.2006.01.003","article-title":"Current antimicrobial resistance profiles among methicillin-resistant Staphylococcus aureus encountered in the outpatient setting","volume":"55","author":"Draghi","year":"2006","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2012.05.012_bb0065","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1128\/AAC.48.8.3169-3171.2004","article-title":"In vitro activities of telithromycin, linezolid, and quinupristin-dalfopristin against Streptococcus pneumoniae with macrolide resistance due to ribosomal mutations","volume":"48","author":"Farrell","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2012.05.012_bb0055","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.diagmicrobio.2009.10.011","article-title":"Linezolid surveillance program results for 2008 (LEADER Program for 2008)","volume":"65","author":"Farrell","year":"2009","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2012.05.012_bb0060","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1128\/AAC.01729-10","article-title":"LEADER Program results for 2009: an activity and spectrum analysis of linezolid using 6,414 clinical isolates from the United States (56 medical centers)","volume":"55","author":"Farrell","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2012.05.012_bb0070","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2174\/1568005014606099","article-title":"The discovery of linezolid, the first oxazolidinone antibacterial agent","volume":"1","author":"Ford","year":"2001","journal-title":"Curr Drug Targets Infect Disord"},{"key":"10.1016\/j.diagmicrobio.2012.05.012_bb0075","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S0149-2918(01)80043-6","article-title":"Linezolid: an oxazolidinone antimicrobial agent","volume":"23","author":"Fung","year":"2001","journal-title":"Clin Ther"},{"key":"10.1016\/j.diagmicrobio.2012.05.012_bb0090","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1128\/AAC.40.3.720","article-title":"In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones","volume":"40","author":"Jones","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2012.05.012_bb0110","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/jac\/dki437","article-title":"Oxazolidinone susceptibility patterns in 2004: report from the Zyvox\u00ae Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations","volume":"57","author":"Jones","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2012.05.012_bb0080","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.diagmicrobio.2007.06.004","article-title":"LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers)","volume":"59","author":"Jones","year":"2007","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2012.05.012_bb0085","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.diagmicrobio.2007.06.001","article-title":"Zyvox\u00ae Annual Appraisal of Potency and Spectrum Program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries","volume":"59","author":"Jones","year":"2007","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2012.05.012_bb0115","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1128\/AAC.01496-06","article-title":"Activity of linezolid against 3,251 strains of uncommonly isolated Gram-positive organisms: report from the SENTRY Antimicrobial Surveillance Program","volume":"51","author":"Jones","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2012.05.012_bb0105","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.diagmicrobio.2008.10.010","article-title":"United States resistance surveillance results for linezolid (LEADER Program for 2007)","volume":"62","author":"Jones","year":"2008","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2012.05.012_bb0095","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.diagmicrobio.2009.03.001","article-title":"ZAAPS International Surveillance Program (2007) for linezolid resistance: results from 5591 Gram-positive clinical isolates in 23 countries","volume":"64","author":"Jones","year":"2009","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2012.05.012_bb0100","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.diagmicrobio.2009.10.001","article-title":"Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008","volume":"65","author":"Jones","year":"2009","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2012.05.012_bb0120","doi-asserted-by":"crossref","first-page":"5275","DOI":"10.1128\/AAC.01032-09","article-title":"Mutations in ribosomal protein L3 are associated with oxazolidinone resistance in staphylococci of clinical origin","volume":"53","author":"Locke","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2012.05.012_bb0125","doi-asserted-by":"crossref","first-page":"5265","DOI":"10.1128\/AAC.00871-09","article-title":"Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700)","volume":"53","author":"Locke","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2012.05.012_bb0130","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1128\/AAC.00131-06","article-title":"The cfr rRNA methyltransferase confers resistance to phenicols, lincosamides, oxazolidinones, pleuromutilins, and streptogramin A antibiotics","volume":"50","author":"Long","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2012.05.012_bb0135","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1128\/AAC.00231-08","article-title":"First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States","volume":"52","author":"Mendes","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2012.05.012_bb0140","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1093\/jac\/dkq331","article-title":"Assessment of linezolid resistance mechanisms among Staphylococcus epidermidis causing bacteraemia in Rome, Italy","volume":"65","author":"Mendes","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2012.05.012_bb0145","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.diagmicrobio.2007.08.007","article-title":"Prevalence of multidrug-resistant, methicillin-resistant Staphylococcus aureus in the United States: findings of the stratified analysis of the 2004 to 2005 LEADER Surveillance Programs","volume":"60","author":"Pillar","year":"2008","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2012.05.012_bb0150","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.diagmicrobio.2004.12.013","article-title":"Trends in linezolid susceptibility patterns in 2002: report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program","volume":"52","author":"Ross","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2012.05.012_bb0155","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ijantimicag.2006.09.025","article-title":"Oxazolidinone susceptibility patterns for 2005: international report from the Zyvox\u00ae Annual Appraisal of Potency and Spectrum Study","volume":"29","author":"Ross","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2012.05.012_bb0160","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1517\/13543784.8.8.1195","article-title":"Mechanism of action of the oxazolidinone antibacterial agents","volume":"8","author":"Shinabarger","year":"1999","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.diagmicrobio.2012.05.012_bb0165","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/jac\/dki355","article-title":"Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies","volume":"56","author":"Shorr","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2012.05.012_bb0175","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1086\/340353","article-title":"Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections","volume":"34","author":"Stevens","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2012.05.012_bb0170","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1586\/14787210.2.1.51","article-title":"A review of linezolid: the first oxazolidinone antibiotic","volume":"2","author":"Stevens","year":"2004","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.diagmicrobio.2012.05.012_bb0180","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1111\/j.1365-2958.2007.05744.x","article-title":"Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid","volume":"64","author":"Toh","year":"2007","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.diagmicrobio.2012.05.012_bb0185","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1128\/AAC.49.6.2260-2266.2005","article-title":"Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections","volume":"49","author":"Weigelt","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2012.05.012_bb0190","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1128\/AAC.49.8.3554-3557.2005","article-title":"Novel mechanism of resistance to oxazolidinones, macrolides, and chloramphenicol in ribosomal protein L4 of the pneumococcus","volume":"49","author":"Wolter","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2012.05.012_bb0195","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/S0149-2918(03)80118-2","article-title":"Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia","volume":"25","author":"Wunderink","year":"2003","journal-title":"Clin Ther"},{"key":"10.1016\/j.diagmicrobio.2012.05.012_bb0205","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0012-3692(15)33412-7","article-title":"Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia","volume":"124","author":"Wunderink","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.diagmicrobio.2012.05.012_bb0200","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/cid\/cir895","article-title":"Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study","volume":"54","author":"Wunderink","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2012.05.012_bb0210","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1128\/AAC.40.4.839","article-title":"In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents","volume":"40","author":"Zurenko","year":"1996","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889312001940?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889312001940?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T12:45:01Z","timestamp":1687524301000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889312001940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S0732889312001940"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2012.05.012","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}